U.S. Hospitality Stock News

Iovance Biotherapeutics recently reported Q4 2025 and full-year 2025 results, with revenue rising to US$86.77 million for the quarter and US$263.50 million for the year, alongside lower quarterly net loss and loss per share compared with 2024. At the same time, the company highlighted positive early lifileucel data in aggressive soft tissue sarcomas and secured FDA Fast Track designation for non-small cell lung cancer, underscoring how its first commercial TIL therapy Amtagvi is increasingly...

Earlier this month, Ecolab’s board reshaped its senior team by adding the President title to Chairman and CEO Christophe Beck and splitting the chief operating officer role between Darrell R. Brown as Co-COO – Global Markets and Gregory B. Cook as Co-COO – Global Businesses, while director Victoria J. Reich decided not to stand for re-election and the company affirmed its US$0.73 quarterly dividend. These leadership changes, alongside a new shelf registration for debt securities, suggest...

Applied Optoelectronics (AAOI) closed out FY 2025 with fourth quarter revenue of US$134.3 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$2.0 million loss. This puts the focus squarely on how efficiently that top line is being converted into earnings. The company has seen quarterly revenue move from US$65.2 million in Q3 2024 to US$100.3 million in Q4 2024, then to US$99.9 million in Q1 2025, US$103.0 million in Q2 2025, US$118.6 million in Q3 2025...

Perella Weinberg Partners recently reported quarterly revenues of US$219.2 million, a 2.9% year-on-year decline that still exceeded analyst estimates by a very large margin, alongside an earnings beat. The results highlight how the firm’s operational execution outpaced expectations even as headline revenue slipped, offering a more nuanced picture of performance for investors. Next, we’ll examine how this better-than-expected revenue performance shapes Perella Weinberg Partners’ investment...

Short term moves and recent performance context Berkshire Hathaway (BRK.A) recently closed at US$757,000, with the stock showing a 0.5% move over the past day and a 1.4% gain across the past week, keeping short term performance in focus for investors. See our latest analysis for Berkshire Hathaway. That recent 6% 1 month share price return comes after a softer 90 day share price return of a 1.7% decline and sits alongside a 3 year total shareholder return of about 60%. This suggests longer...

In the fourth quarter and full year ended December 31, 2025, Jones Lang LaSalle reported higher sales and net income year over year, while also completing a multi‑year share repurchase program totaling 6.80 million shares for US$1.40 billion since its November 2019 authorization. The combination of earnings exceeding analyst expectations and management’s plan to direct more capital toward buybacks in 2026 highlights a greater emphasis on capital return alongside operational growth in...

Community Trust Bancorp recently highlighted a quarterly dividend of US$0.53 per share, implying a 3.43% yield and reflecting five consecutive years of annual dividend increases averaging 5.32%. Alongside this dividend profile, the company is guided by a Zacks Consensus Estimate pointing to fiscal 2026 earnings of US$5.79 per share, suggesting investors are closely watching how income and earnings trends align. With this backdrop of consistent dividend growth, we’ll examine how the company’s...

Synopsys (NasdaqGS:SNPS) has appointed Peter A. Shimer, a long time Deloitte executive, to its board of directors and audit committee. The company is not renominating two sitting directors, resulting in a refreshed board composition. Shimer brings extensive financial, operational and AI related governance experience, including work with AI focused cancer research alliances. For investors watching Synopsys at a share price of $414.0, this board change arrives after mixed recent returns. The...

In February 2026, STAAR Surgical announced that the FDA approved an expanded age indication for its EVO/EVO+ Visian Implantable Collamer Lenses, extending U.S. use from ages 21–45 to 21–60 following three-year safety data. This broader label meaningfully enlarges the potential U.S. candidate pool for EVO ICL, especially among adults aged 46–60 who were previously excluded. We’ll now examine how opening EVO ICL access to patients up to age 60 could reshape STAAR Surgical’s longer-term...

Lantheus Holdings (LNTH) just posted fourth quarter results that topped Wall Street expectations on both revenue and earnings, while issuing 2026 guidance that sits below consensus and reflects expected pressure on key products. See our latest analysis for Lantheus Holdings. The latest earnings beat and guidance update come after a sharp rebound in the 3‑month share price return of 27.25% and a 1‑month share price return of 12.97%, even though the 1‑year total shareholder return is still down...

In recent months, Victoria’s Secret raised its full-year net sales outlook and projected improved adjusted operating income, supported by strong international retail sales, particularly in China, as it continued its post-pandemic brand repositioning. Alongside this operational progress, the company has leaned into cultural relevance through the revived Victoria’s Secret Fashion Show and celebrity collaborations to deepen engagement with younger, global consumers. With management’s upgraded...

If you are wondering whether Hinge Health at around US$42.76 is offering good value or asking too much, you are not alone. This article is designed to help you frame that question clearly. Over the short term, the stock has moved, with a 3.5% return over the last 7 days, 13.6% over the last 30 days, and a 6.1% decline year to date. These changes can influence how investors think about both upside and risk. Recent coverage has focused on Hinge Health as a listed digital healthcare name and on...

Healthpeak Properties (DOC) is in focus after confirming that CEO Scott Brinker will speak at the Citi 2026 Global Property CEO Conference, while the company continues work on the Janus Living senior housing REIT IPO. See our latest analysis for Healthpeak Properties. Recent interest around the CEO’s Citi conference appearance and the Janus Living IPO work comes as the stock shows a 1-day share price return of 0.97% and a 7-day share price return of 4.06%. The 1-year total shareholder return...

Coupang FY 2025 Results Set Up a Mixed but Margin Focused Story Coupang (CPNG) closed FY 2025 with fourth quarter revenue of US$8.8b and a basic EPS loss of US$0.01, as net income excluding extra items came in at a US$26m loss against a backdrop of growing full year scale. The company has seen quarterly revenue step up from US$7.9b in Q4 2024 to between US$7.9b and US$9.3b through 2025. Basic EPS has moved between a profit of US$0.06 and a small loss in the latest quarter, setting up a TTM...

If you are wondering whether Nova's share price still reflects good value after a strong run, this article is for you. We will walk through what the current market price might be implying about the business. Nova's stock last closed at US$438.86, with a 7 day return of a 0.5% decline, a 30 day return of a 9.9% decline, a year to date return of 26.3% and a 1 year return of 83.5%, while the 3 year return is very large and the 5 year return is also very large. Recent news coverage around Nova...

Opera (NasdaqGS:OPRA) posts FY 2025 results Opera (NasdaqGS:OPRA) closed out FY 2025 with fourth quarter revenue of US$176.7 million and basic EPS of US$0.62, rounding off a trailing twelve month run of US$614.4 million in revenue and EPS of US$1.21 as earnings grew 34.1% over the past year. The company has seen revenue move from US$480.6 million on a trailing basis at the end of 2024 to US$614.4 million by the end of 2025, while trailing net profit margin edged up from 16.8% to 17.6%. With...

ABM Industries, NYSE:ABM, is repositioning itself as a defensive, cash-focused services company. Management is prioritizing margin protection through wage inflation management and contract repricing. The company is reshaping its portfolio with selective divestitures and greater emphasis on technology-enabled services. ABM Industries, trading at $44.5, is presenting itself as a steadier, lower volatility option within the outsourced facilities and services space. The effort is playing out...

CRA International (CRAI) has drawn investor attention after recent share price moves, with the stock up 3.1% over the past week but showing negative returns over the past month and past 3 months. See our latest analysis for CRA International. That recent 3.1% one day share price gain sits against a weaker backdrop, with a 30 day share price return of 7.5% and a year to date share price return of a 13.9% decline. However, longer term total shareholder returns of 62% over three years and 178%...

Innodata (INOD) has just wrapped up FY 2025 with fourth quarter revenue of US$72.4 million and basic EPS of US$0.28, alongside trailing twelve month revenue of US$251.7 million and EPS of US$1.01. The company has seen quarterly revenue move from US$52.2 million in Q3 2024 to US$72.4 million in Q4 2025. Basic EPS has ranged from US$0.60 in Q3 2024 to between US$0.23 and US$0.28 across the 2025 quarters, setting up a picture where growing sales are rubbing against tighter margins and leaving...

If you are wondering whether SoFi Technologies shares are offering good value right now, you are not alone. This article will walk through what the current price actually reflects. The stock recently closed at US$17.76, with returns of a 6.6% decline over 7 days, a 27.8% decline over 30 days, a 35.3% decline year to date, but a 22.7% gain over 1 year and a very large gain over 3 years. These moves have come as SoFi remains a widely watched name in US fintech, with ongoing attention on its...

Eli Lilly (LLY) is back in focus after fresh clinical data showed its injectable GLP-1 drug tirzepatide and oral candidate orforglipron outperforming Novo Nordisk rivals in weight loss and blood sugar control. See our latest analysis for Eli Lilly. The latest tirzepatide and orforglipron data slot into a busy few weeks for Eli Lilly, with Zepbound’s new KwikPen format, expanded data across Omvoh and Taltz combinations, and regulatory progress for Olumiant helping keep attention on its obesity...

Assessing Pilgrim's Pride after recent share performance Pilgrim's Pride (PPC) has drawn fresh attention after a recent 4.1% daily gain and a 3.4% move over the past week, prompting investors to reassess the stock's recent return profile. See our latest analysis for Pilgrim's Pride. Looking past the latest move, Pilgrim's Pride has a 90 day share price return of 13.46% and a 3 year total shareholder return of 110.44%, which suggests recent momentum sits against a much stronger longer term...

In recent weeks, Alibaba Group Holding, through its cloud unit, launched a low-cost, multi-model AI coding subscription that bundles access to several leading Chinese open-source models, including its own Qwen 3.5, while also advancing its AI infrastructure with its self-developed Zhenwu 810E chip. This push into flexible, bundled AI tools signals a shift in Alibaba’s focus from its traditional e-commerce roots toward building a broader AI and cloud ecosystem for developers and...

If you are wondering whether Federal Home Loan Mortgage at around US$6.44 is still offering value after its big run in recent years, you are not alone. The stock has seen a 17.3% return over the past year, even after a 37.8% year to date decline, a 9.9% drop over 30 days and an 11.7% fall over the last week, so the price is still adjusting after a very large 3 year gain that is well over 10x. Recent coverage has focused on Federal Home Loan Mortgage as part of the broader conversation around...